NSCLC中SP263 PD-L1评分观察者间可靠性研究
本研究评估VENTANA PD-L1(SP263)检测在非小细胞肺癌(NSCLC)肿瘤细胞(TC)评分中的观察者间可靠性。六名欧洲肺病理学家独立对200例存档NSCLC切除标本进行TC评分,172例可评估样本显示病理学家间强相关(R²>0.89),组内相关系数0.96,TC≥1%总体一致率>90%,TC≥25%和≥50%一致率>94%。结论认为SP263检测的TC评分在NSCLC中高度可重复。
要点
- SP263检测在NSCLC肿瘤细胞PD-L1评分中观察者间可靠性高(ICC=0.96)。
- TC≥1%时总体一致率>90%,TC≥25%和≥50%时一致率>94%。
- Fleiss kappa显示TC≥1%为实质性一致,TC≥25%和≥50%为几乎完美一致。
核心结论
- SP263检测在NSCLC肿瘤细胞PD-L1评分中具有高度可重复性,支持其用于筛选抗PD-1/PD-L1治疗患者。
研究设计与样本
- 六名执业欧洲肺病理学家独立对200例存档、商业来源的福尔马林固定石蜡包埋NSCLC切除标本进行SP263检测的PD-L1肿瘤细胞评分。
主要发现
- 172例样本结果显示病理学家间TC评分强相关(R²>0.89),组内相关系数为0.96。
- TC≥1%时总体一致率>90%,TC≥25%和≥50%时总体一致率>94%。
- Fleiss kappa显示TC≥1%为实质性一致,TC≥25%和≥50%为几乎完美一致。
关键数值与推荐
- TC≥1%总体一致率>90%,TC≥25%和≥50%总体一致率>94%。
- 组内相关系数0.96,病理学家间配对相关R²>0.89。
临床怎么用
- SP263检测的TC评分可靠,可用于NSCLC患者抗PD-1/PD-L1治疗的筛选。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
INTRODUCTION: The VENTANA PD-L1 (SP263) Assay is approved for use with anti-programmed cell death-1/programmed cell death ligand-1 (PD-1/PD-L1) therapies in NSCLC and urothelial carcinoma. Here, we investigate interobserver reliability of the SP263 assay, applied to PD-L1 scoring of tumor cells (TCs) in NSCLC. METHODS: Six practicing European pulmonary pathologists independently scored the proportion of TCs expressing PD-L1 (TC score) from 200 archival, commercially sourced, formalin-fixed paraffin-embedded NSCLC resections stained using the SP263 assay. Agreement in scores was analyzed using the intraclass correlation coefficient and concordance in patient's classification using Fleiss' kappa. RESULTS: Results from 172 samples showed strong pair-wise correlations between pathologists (R2 >0.89) for TC scoring with an intraclass correlation coefficient of 0.96. Overall agreement was greater than 90% for TC of 1% and above, and greater than 94% for TCs of at least 25% and at least 50%. Fleiss' kappa showed substantial agreement for TC of 1% and above, and almost perfect agreement for TCs of at least 25% and at least 50%. CONCLUSIONS: Assessment of TC score in NSCLC was highly reproducible using the SP263 assay, building confidence in the accuracy of this assay in selection of patients for anti-PD-1/PD-L1 therapy.
引用
- Williams GH, Nicholson AG, Snead DRJ, et al. Interobserver Reliability of Programmed Cell Death Ligand-1 Scoring Using the VENTANA PD-L1 (SP263) Assay in NSCLC. J Thorac Oncol. 2019. PMID: 31778799. doi:10.1016/j.jtho.2019.11.010
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。